Aerosol formulations containing salmeterol xinafoate, an anticholinergic agent and tetrafluoroethane
US6238647A · kind A · utility
19Cited by
39References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 2, 1999 |
| Grant date | May 29, 2001 |
| Priority date | — |
| Expiry date | Nov 2, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P11/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.